288 related articles for article (PubMed ID: 17673939)
1. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.
Taylor KM; Morgan HE; Smart K; Zahari NM; Pumford S; Ellis IO; Robertson JF; Nicholson RI
Mol Med; 2007; 13(7-8):396-406. PubMed ID: 17673939
[TBL] [Abstract][Full Text] [Related]
2. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters.
Taylor KM; Morgan HE; Johnson A; Hadley LJ; Nicholson RI
Biochem J; 2003 Oct; 375(Pt 1):51-9. PubMed ID: 12839489
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients.
Kasper G; Weiser AA; Rump A; Sparbier K; Dahl E; Hartmann A; Wild P; Schwidetzky U; Castaños-Vélez E; Lehmann K
Int J Cancer; 2005 Dec; 117(6):961-73. PubMed ID: 15986450
[TBL] [Abstract][Full Text] [Related]
4. The LZT proteins; the LIV-1 subfamily of zinc transporters.
Taylor KM; Nicholson RI
Biochim Biophys Acta; 2003 Apr; 1611(1-2):16-30. PubMed ID: 12659941
[TBL] [Abstract][Full Text] [Related]
5. A distinct role in breast cancer for two LIV-1 family zinc transporters.
Taylor KM
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1247-51. PubMed ID: 19021534
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters.
Taylor KM; Morgan HE; Johnson A; Nicholson RI
Biochem J; 2004 Jan; 377(Pt 1):131-9. PubMed ID: 14525538
[TBL] [Abstract][Full Text] [Related]
7. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
Taylor KM; Vichova P; Jordan N; Hiscox S; Hendley R; Nicholson RI
Endocrinology; 2008 Oct; 149(10):4912-20. PubMed ID: 18583420
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production.
Bagheri S; Hashemi M; Alirahimi E; Habibi-Anbouhi M; Kazemi-Lomedasht F; Behdani M
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):70-74. PubMed ID: 31009334
[TBL] [Abstract][Full Text] [Related]
9. Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14.
Taylor KM; Morgan HE; Johnson A; Nicholson RI
FEBS Lett; 2005 Jan; 579(2):427-32. PubMed ID: 15642354
[TBL] [Abstract][Full Text] [Related]
10. Zinc and cancer: implications for LIV-1 in breast cancer.
Grattan BJ; Freake HC
Nutrients; 2012 Jul; 4(7):648-75. PubMed ID: 22852056
[TBL] [Abstract][Full Text] [Related]
11. Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7.
Shen H; Qin H; Guo J
Mol Biol Rep; 2009 Apr; 36(4):653-9. PubMed ID: 18330719
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
14. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
Sussman D; Smith LM; Anderson ME; Duniho S; Hunter JH; Kostner H; Miyamoto JB; Nesterova A; Westendorf L; Van Epps HA; Whiting N; Benjamin DR
Mol Cancer Ther; 2014 Dec; 13(12):2991-3000. PubMed ID: 25253783
[TBL] [Abstract][Full Text] [Related]
15. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
16. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
17. LIV-1 breast cancer protein belongs to new family of histidine-rich membrane proteins with potential to control intracellular Zn2+ homeostasis.
Taylor KM
IUBMB Life; 2000 Apr; 49(4):249-53. PubMed ID: 10995024
[TBL] [Abstract][Full Text] [Related]
18. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
[TBL] [Abstract][Full Text] [Related]
19. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
20. The LIV-1 Subfamily of Zinc Transporters: From Origins to Present Day Discoveries.
Taylor KM
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
